The present study investigated the levels of circulating cell-free DNA (cfDNA) in plasma from patients with metastatic colorectal cancer (mCRC) in relation to third-line treatment with cetuximab and irinotecan and the quantitative relationship of cfDNA with tumor-specific mutations in plasma.
Spindler, K-L. G., Pallisgaard, N., Vogelius, I. S., & Jakobsen, A. (2012). Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clinical Cancer Research, 18(4), 1177-85. https://doi.org/10.1158/1078-0432.CCR-11-0564